OFOrli Friedman-Eldar

Orli Friedman-Eldar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Orli Friedman-Eldar has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Dido Franceschi

    Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, USA

    4 shared publications
  • Eli Avisar

    Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, USA

    4 shared publications
  • Neha Goel

    Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, USA

    4 shared publications
  • Anne-Sophie Lessard

    Division of Plastic Surgery, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, USA

    3 shared publications
  • Eli Avisar

    University of Miami Miller School of Medicine, Miami, FL

    3 shared publications
  • Mecker G. Moller

    University of Miami, Miller School of Medicine, Division of Surgical Oncology, Miami, FL, USA

    3 shared publications

Latest Publications

  • Open Access

    Epigenetic heterogeneity in breast tumours informs diagnosis and prognosis

    by Noa Furth, Christina Riemenschneider, Yishai Arieli, Matan Avni, Michael-Yakov Povolotski, Hadas Yung, Shiri Karagach, Ofir Atrakchi, Nir Erez, Tomer-Meir Salame, et al.

    Breast cancer, the most diagnosed cancer among women, is stratified by gene expression patterns into luminal and basal-like subtypes, and the latter is associated with worse prognosis1-3. Recent advances in single-cell technologies have underscored the presence of intratumour heterogeneity, which poses substantial challenges in cancer treatment and achieving long-term disease-free survival4-7. Here we extensively profile epigenetic heterogeneity in a cohort of treatment-naive human luminal tumours, which were obtained directly after surgical resection. By applying a single-cell epigenetic approach based on cytometry by time-of-flight, we identify a recurrent subpopulation of basal-like cells in luminal tumours with a conserved epigenetic signature across patients. These basal-like cells, also identified by deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling. Direct comparison of single-cell proteomic and genomic profiling of monomethylation and trimethylation of histone 3 on lysine 4 revealed that these marks are key features associated with loss of luminal identity. Finally, we highlight the potential of concomitant single-molecule profiling of histone modifications on cell-free nucleosomes in blood as an epigenetic liquid biopsy approach for early diagnosis of breast cancer. Moreover, the epigenetic basal signature measured in blood is linked to prognosis, which enables the identification of patients at increased risk for disease relapse.

  • Axillary Reverse Lymphatic Mapping in the Treatment of Axillary Accessory Breast Cancer: A Case Report and Review of Management

    by Orli Friedman-Eldar, Siarhei Melnikau, Youley Tjendra, Eli Avisar

    Accessory breast tissue is a rare aberration of normal breast development, that presents most commonly in the axilla. Similar to normal breast tissue, it can undergo physiologic and pathologic changes, including malignant transformation. We report a rare case of accessory breast cancer, treated with surgical resection and axillary reverse mapping (ARM), and review current literature focusing on management. We report a 68-year-old female with a history of left breast cancer treated with lumpectomy and axillary dissection, who later developed in-breast recurrence treated with re-lumpectomy and sentinel node biopsy which mapped at the contralateral (right) axilla, but was negative. Two years later screening imaging revealed right axillary tail focal asymmetry with two spiculated masses. Core biopsy showed invasive ductal carcinoma (IDC), and histologic examination of the biopsy could not determine whether this represents a new primary breast cancer or axillary metastasis from the contralateral site. She underwent lumpectomy of the two masses and sentinel node biopsy. During surgery, the masses were identified in the axilla itself, rather than the axillary tail. Final pathology revealed IDC, pT1N0(sn), and extensive ductal carcinoma in situ (DCIS). Due to positive margins, she underwent re-lumpectomy with ARM. Final pathology revealed residual DCIS with negative new margins. The patient was referred for adjuvant radiotherapy. Accessory axillary breast tissue can be confused with axillary tail tissue. It is necessary for the surgeon to distinguish between them by meticulous physical examination and radiologic evaluation, as resection of axillary breast tissue may warrant reverse lymphatic mapping for lymphedema prevention.


  • Open Access

    Stalled at the intersection: insurance status and disparities in post-mastectomy breast reconstruction

    by Orli Friedman-Eldar, Jonathan Burke, Iago de Castro Silva, Camille C. Baumrucker, Fernando Valle, Anne-Sophie Lessard, Wrood Kassira, Dido Franceschi, Susan B. Kesmodel, Eli Avisar, et al.

    Purpose Post-mastectomy breast reconstruction (PMBR) is an important component of breast cancer treatment, but disparities relative to insurance status persist despite legislation targeting the issue. We aimed to study this relationship in a large health system combining a safety-net hospital and a private academic center. Methods Data were collected on all patients who underwent mastectomy for breast cancer from 2011 to 2019 in a private academic center and an adjacent public safety-net hospital served by the same surgical teams. Multivariable logistic regression was used to assess the effect of insurance status on PMBR, controlling for covariates that included socioeconomic, demographic, and clinical factors. Results Of 1554 patients undergoing mastectomy for breast cancer, 753 (48.5%) underwent PMBR, of which 592 (79.9%) were privately insured, 50 (6.7%) Medicare, 68 (9.2%) Medicaid, and 31 (4.2%) uninsured. Multivariable logistic regression showed a significantly higher likelihood of not undergoing PMBR for uninsured (OR 6.0, 95% CI 3.7–9.8; p < 0.0001), Medicare (OR 1.9, (95% CI 1.2–3.0; p = 0.006), and Medicaid (OR 1.5, 95% CI 1.0–2.3; p = 0.04) patients compared with privately insured patients. Age, stage, race and ethnicity, and hospital type confounded this relationship. Conclusion Patients without health insurance have dramatically reduced access to PMBR compared to those with private insurance. Expanding access to this important procedure is essential to achieve greater health equity for breast cancer patients.


  • Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes

    by Orli Friedman-Eldar, Tolga Ozmen, Salah James El Haddi, Neha Goel, Youley Tjendra, Susan B. Kesmodel, Mecker G. Moller, Dido Franceschi, Christina Layton, Eli Avisar

    One potential benefit of neoadjuvant therapy (NAT) in node-positive, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (H


  • ASO Visual Abstract: Axillary Response to Neoadjuvant Therapy in Node-Positive ER+/HER2- Breast Cancer Patients—Predictors and Oncologic Outcomes

    by Orli Friedman-Eldar, Tolga Ozmen, Salah James El Haddi, Neha Goel, Youley Tjendra, Susan B. Kesmodel, Mecker G. Moller, Dido Franceschi, Christina Layton, Eli Avisar

  • Persistent and interdependent: Racial disparities and their mechanisms in postmastectomy breast reconstruction

    by Jonathan Burke, Orli Friedman-Eldar, Gili Halfteck, Iago de Castro Silva, Camille C. Baumrucker, Fernando Valle Reyes, Anne-Sophie Lessard, Wrood Kassira, Dido Franceschi, Susan B. Kesmodel, et al.


  • Open Access

    Stalled at the Intersection: Insurance Status and Disparities in Post Mastectomy Breast Reconstruction

    by Orli Friedman-Eldar, Jonathan Burke, Iago de Castro Silva, Camille C Baumrucker, Fernando Valle, Anne-Sophie Lessard, Wrood Kassira, Dido Franceschi, Susan B Kesmodel, Eli Avisar, et al.

    PurposePost-mastectomy breast reconstruction (PMBR) is an important component of breast cancer treatment, but disparities relative to insurance status persist despite legislation targeting the issue. We aimed to study this relationship in a large health system combining a safety net hospital and a private academic center.MethodsData were collected on all patients who underwent mastectomy for breast cancer from 2011-2019 in a private academic center and an adjacent public safety-net hospital served by same surgical teams. Multivariable logistic regression was used to assess the effect of insurance status on PMBR, controlling for covariates that included socioeconomic, demographic, and clinical factors.ResultsOf 1,554 patients undergoing mastectomy for breast cancer, 753 (48.5%) underwent PMBR. Out of them, 741 had insurance type recorded, with 592 (79.9%) privately insured patients, 50 (6.7%) Medicare, 68 (9.2%) Medicaid, and 31 (4.2%) uninsured patients. Multivariable logistic regression showed a significantly lower likelihood of undergoing PMBR for uninsured (OR 6.9, 95% CI: 4.1-11.7; p<0.0001), Medicare (OR 2.0, (5% CI: 1.2-3.3; p=0.004), and Medicaid (OR 1.7, 95% CI:1.1-2.7; p=0.02) patients, compared with privately insured patients. Age, stage, race, and hospital type confounded this relationship.ConclusionPatients without health insurance have dramatically reduced access to PMBR compared to those with private insurance. Expanding access to this important procedure is essential to achieve greater health equity for breast cancer patients.